{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:16:27Z","timestamp":1791918987133,"version":"4.3.4"},"reference-count":127,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T00:00:00Z","timestamp":1617667200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The pathophysiology of hypertension and cancer are intertwined. Hypertension has been associated with an increased likelihood of developing certain cancers and with higher cancer-related mortality. Moreover, various anticancer therapies have been reported to cause new elevated blood pressure or worsening of previously well-controlled hypertension. Hypertension is a well-established risk factor for the development of cardiovascular disease, which is rapidly emerging as one of the leading causes of death and disability in patients with cancer. In this review, we discuss the relationship between hypertension and cancer and the role that hypertension plays in exacerbating the risk for anthracycline- and trastuzumab-induced cardiomyopathy. We then review the common cancer therapies that have been associated with the development of hypertension, including VEGF inhibitors, small molecule tyrosine kinase inhibitors, proteasome inhibitors, alkylating agents, glucocorticoids, and immunosuppressive agents. When available, we present strategies for blood pressure management for each drug class. Finally, we discuss blood pressure goals for patients with cancer and strategies for assessment and management. It is of utmost importance to maintain optimal blood pressure control in the oncologic patient to reduce the risk of chemotherapy-induced cardiotoxicity and to decrease the risk of long-term cardiovascular disease.<\/jats:p>","DOI":"10.1186\/s40959-021-00101-2","type":"journal-article","created":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T09:02:36Z","timestamp":1617699756000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Etiology and management of hypertension in patients with cancer"],"prefix":"10.1186","volume":"7","author":[{"given":"Turab","family":"Mohammed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghana","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes S.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,6]]},"reference":[{"key":"101_CR1","doi-asserted-by":"publisher","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","volume":"9","author":"MW Bloom","year":"2016","unstructured":"Bloom MW, Hamo CE, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging. Circ Heart Fail. Lippincott Williams and Wilkins. 2016;9:e002661.","journal-title":"Circ Heart Fail"},{"key":"101_CR2","unstructured":"Definition of cardiotoxicity - NCI Dictionary of Cancer Terms - National Cancer Institute [Internet]. [cited 2020 Aug 8]. Available from: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/cardiotoxicity"},{"key":"101_CR3","doi-asserted-by":"publisher","first-page":"R64","DOI":"10.1186\/bcr2901","volume":"13","author":"JL Patnaik","year":"2011","unstructured":"Patnaik JL, Byers T, DiGuiseppi C, Dabelea D, Denberg TD. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: A retrospective cohort study. Breast Cancer Res. BioMed Central. 2011;13:R64.","journal-title":"Breast Cancer Res. BioMed Central"},{"key":"101_CR4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijcard.2019.01.082","volume":"281","author":"G Tini","year":"2019","unstructured":"Tini G, Sarocchi M, Tocci G, Arboscello E, Ghigliotti G, Novo G, et al. Arterial hypertension in cancer: the elephant in the room. Int J Cardiol. Elsevier Ireland Ltd. 2019;281:133\u20139. https:\/\/doi.org\/10.1016\/j.ijcard.2019.01.082.","journal-title":"Int J Cardiol"},{"issue":"3","key":"101_CR5","first-page":"263","volume":"38","author":"E Mouhayar","year":"2011","unstructured":"Mouhayar E, Salahudeen A. Hypertension in Cancer patients. Tex Heart Inst J. 2011;38(3):263\u20135.","journal-title":"Tex Heart Inst J"},{"issue":"3","key":"101_CR6","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5935\/abc.20150011","volume":"104","author":"VB de Souza","year":"2015","unstructured":"de Souza VB, Silva EN, Ribeiro ML. Martins W de a. hypertension in patients with cancer. Arq Bras Cardiol. 2015;104(3):246\u201352. https:\/\/doi.org\/10.5935\/abc.20150011.","journal-title":"Arq Bras Cardiol"},{"key":"101_CR7","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0140-6736(75)91826-7","volume":"305","author":"AR Dyer","year":"1975","unstructured":"Dyer AR, Berkson DM, Stamler J, Lindberg HA, Stevens E. HIGH BLOOD-PRESSURE: a RISK FACTOR FOR CANCER MORTALITY ? Lancet. 1975;305:1051\u20136.","journal-title":"Lancet"},{"key":"101_CR8","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/HJH.0000000000000770","volume":"34","author":"JL Harding","year":"2016","unstructured":"Harding JL, Sooriyakumaran M, Anstey KJ, Adams R, Balkau B, Brennan-Olsen S, et al. Hypertension, antihypertensive treatment and cancer incidence and mortality. J Hypertens. Lippincott Williams and Wilkins. 2016;34:149\u201355.","journal-title":"J Hypertens"},{"key":"101_CR9","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/ijc.28334","volume":"134","author":"A Milan","year":"2014","unstructured":"Milan A, Puglisi E, Ferrari L, Bruno G, Losano I, Veglio F. Arterial hypertension and cancer. Int J Cancer. Wiley-Liss Inc. 2014;134:2269\u201377.","journal-title":"Int J Cancer"},{"key":"101_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1097\/EDE.0b013e3182300720","volume":"22","author":"JS Colt","year":"2011","unstructured":"Colt JS, Schwartz K, Graubard BI, Davis F, Ruterbusch J, Digaetano R, et al. Hypertension and risk of renal cell carcinoma among white and black Americans. Epidemiology. NIH Public Access. 2011;22:797\u2013804.","journal-title":"Epidemiology"},{"key":"101_CR11","first-page":"802","volume":"59","author":"T Stocks","year":"2012","unstructured":"Stocks T, Van Hemelrijck M, Manjer J, Bj\u00f8rge T, Ulmer H, Hallmans G, et al. Blood pressure and risk of cancer incidence and mortality in the metabolic syndrome and Cancer project. Hypertens Dallas Tex 1979. Lippincott Williams & WilkinsHagerstown, MD. 2012;59:802\u201310.","journal-title":"Hypertens Dallas Tex 1979"},{"key":"101_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0002-9343(02)01049-5","volume":"112","author":"E Grossman","year":"2002","unstructured":"Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med. Elsevier Inc. 2002;112:479\u201386.","journal-title":"Am J Med"},{"key":"101_CR13","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1161\/CIRCULATIONAHA.115.020406","volume":"133","author":"RJ Koene","year":"2016","unstructured":"Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation Lippincott Williams and Wilkins. 2016;133:1104\u201314.","journal-title":"Circulation"},{"key":"101_CR14","doi-asserted-by":"publisher","unstructured":"Hildebrandt MAT, Reyes M, Wu X, Pu X, Thompson KA, Ma J, Landstrom AP, Morrison AC, Ater JL. Hypertension susceptibility loci are associated with Anthracycline-related Cardiotoxicity in long-term childhood Cancer survivors. Sci Rep. 2017;7(1):9698. https:\/\/doi.org\/10.1038\/s41598-017-09517-2.","DOI":"10.1038\/s41598-017-09517-2"},{"issue":"2","key":"101_CR15","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185\u2013229. https:\/\/doi.org\/10.1124\/pr.56.2.6.","journal-title":"Pharmacol Rev"},{"issue":"5","key":"101_CR16","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD von Hoff","year":"1979","unstructured":"von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710\u20137. https:\/\/doi.org\/10.7326\/0003-4819-91-5-710.","journal-title":"Ann Intern Med"},{"key":"101_CR17","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","volume":"26","author":"DL Hershman","year":"2008","unstructured":"Hershman DL, RB MB, Eisenberger A, Tsai WY, Grann VR, Jacobson JS. Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin\u2019s lymphoma. J Clin Oncol Off J Am Soc Clin Oncol. American Society of Clinical Oncology. 2008;26:3159\u201365.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"25","key":"101_CR18","doi-asserted-by":"publisher","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","volume":"25","author":"MC Pinder","year":"2007","unstructured":"Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol Proc Am Soc Clin Oncol. 2007;25(25):3808\u201315, Congestive Heart Failure in Older Women Treated With Adjuvant Anthracycline Chemotherapy for Breast Cancer. https:\/\/doi.org\/10.1200\/JCO.2006.10.4976.","journal-title":"J Clin Oncol Proc Am Soc Clin Oncol"},{"key":"101_CR19","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1161\/01.CIR.96.8.2641","volume":"96","author":"SE Lipshultz","year":"1997","unstructured":"Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. Lippincott Williams and Wilkins. 1997;96:2641\u20138.","journal-title":"Circulation"},{"key":"101_CR20","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience. J Clin Oncol. Am Soc Clin Oncol (ASCO). 2002;20:1215\u201321.","journal-title":"J Clin Oncol"},{"key":"101_CR21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1006\/mgme.2000.3043","volume":"71","author":"MS Horenstein","year":"2000","unstructured":"Horenstein MS, Vander Heide RS, L\u2019Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab. Academic Press Inc. 2000;71:436\u201344.","journal-title":"Mol Genet Metab"},{"key":"101_CR22","doi-asserted-by":"crossref","unstructured":"Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: The critical role of cellular energetics. J Mol Cell Cardiol. 2006;41(3):389\u2013405.","DOI":"10.1016\/j.yjmcc.2006.06.009"},{"issue":"2","key":"101_CR23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1124\/jpet.117.246140","volume":"364","author":"E Salvatorelli","year":"2018","unstructured":"Salvatorelli E, Menna P, Chello M, Covino E, Minotti G. Low-dose Anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites. J Pharmacol Exp Ther American Society for Pharmacology and Experimental Therapeutics. 2018;364(2):323\u201331. https:\/\/doi.org\/10.1124\/jpet.117.246140.","journal-title":"J Pharmacol Exp Ther American Society for Pharmacology and Experimental Therapeutics"},{"key":"101_CR24","doi-asserted-by":"publisher","unstructured":"Kuriakose RK, Kukreja RC, Xi L. Potential therapeutic strategies for hypertension-exacerbated Cardiotoxicity of anticancer drugs. Oxid Med Cell Longev. 2016;2016:8139861. https:\/\/doi.org\/10.1155\/2016\/8139861.","DOI":"10.1155\/2016\/8139861"},{"key":"101_CR25","first-page":"1276","volume":"341","author":"JJ Hunter","year":"1999","unstructured":"Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. Epstein FH, editor. N Engl J med. Massachusetts Medical Society. 1999;341:1276\u201383.","journal-title":"Massachusetts Medical Society"},{"issue":"11","key":"101_CR26","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jash.2014.08.009","volume":"8","author":"S Szmit","year":"2014","unstructured":"Szmit S, Jurczak W, Zaucha JM, Drozd-Soko\u0142owska J, Spycha\u0142owicz W, Joks M, et al. Pre-existing arterial hypertension as a risk factor for early left ventricular systolic dysfunction following (R)-CHOP chemotherapy in patients with lymphoma. J Am Soc Hypertens. Elsevier Ireland Ltd. 2014;8(11):791\u20139. https:\/\/doi.org\/10.1016\/j.jash.2014.08.009.","journal-title":"J Am Soc Hypertens"},{"key":"101_CR27","doi-asserted-by":"publisher","unstructured":"Balduzzi S, Mantarro S, Guarneri V, Tagliabue L, Pistotti V, Moja L, D'Amico R. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev. 2014;2014(6):CD006242. https:\/\/doi.org\/10.1002\/14651858.CD006242.pub2.","DOI":"10.1002\/14651858.CD006242.pub2"},{"issue":"2","key":"101_CR28","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/1078155214567162","volume":"22","author":"M Gunaldi","year":"2016","unstructured":"Gunaldi M, Duman BB, Afsar CU, Paydas S, Erkisi M, Kara IO, et al. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-Centre study. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract. 2016;22(2):242\u20137. https:\/\/doi.org\/10.1177\/1078155214567162.","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"issue":"3","key":"101_CR29","first-page":"1147","volume":"34","author":"A Sandoo","year":"2014","unstructured":"Sandoo A, Kitas GD, Carmichael AR. Endothelial dysfunction as a determinant of trastuzumab-mediated cardiotoxicity in patients with breast cancer. Anticancer Res. 2014;34(3):1147\u201351.","journal-title":"Anticancer Res"},{"issue":"4","key":"101_CR30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.yexcr.2008.08.015","volume":"315","author":"L Pentassuglia","year":"2009","unstructured":"Pentassuglia L, Sawyer DB. The role of Neuregulin-1beta\/ErbB signaling in the heart. Exp Cell Res. 2009;315(4):627\u201337. https:\/\/doi.org\/10.1016\/j.yexcr.2008.08.015.","journal-title":"Exp Cell Res"},{"issue":"4","key":"101_CR31","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1074\/jbc.M804570200","volume":"284","author":"LI Gordon","year":"2009","unstructured":"Gordon LI, Burke MA, Singh ATK, Prachand S, Lieberman ED, Sun L, et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem. 2009;284(4):2080\u20137. https:\/\/doi.org\/10.1074\/jbc.M804570200.","journal-title":"J Biol Chem"},{"issue":"4","key":"101_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","volume":"20","author":"C Viallard","year":"2017","unstructured":"Viallard C, Larriv\u00e9e B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20(4):409\u201326. https:\/\/doi.org\/10.1007\/s10456-017-9562-9.","journal-title":"Angiogenesis."},{"issue":"9","key":"101_CR33","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1167\/iovs15-16950","volume":"56","author":"TW Hein","year":"2015","unstructured":"Hein TW, Rosa RH, Ren Y, Xu W, Kuo L. VEGF Receptor-2-linked PI3K\/Calpain\/SIRT1 activation mediates retinal arteriolar dilations to VEGF and shear stress. Invest Ophthalmol Vis Sci. 2015;56(9):5381\u20139. https:\/\/doi.org\/10.1167\/iovs15-16950.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"101_CR34","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","volume":"20","author":"Y Zhao","year":"2015","unstructured":"Zhao Y, Adjei AA. Targeting angiogenesis in Cancer therapy: moving beyond vascular endothelial growth factor. Oncologist. 2015;20(6):660\u201373. https:\/\/doi.org\/10.1634\/theoncologist.2014-0465.","journal-title":"Oncologist"},{"issue":"10","key":"101_CR35","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","volume":"17","author":"M Simons","year":"2016","unstructured":"Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17(10):611\u201325. https:\/\/doi.org\/10.1038\/nrm.2016.87.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"101_CR36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.31486\/toj.18.0015","volume":"19","author":"H Kamli","year":"2019","unstructured":"Kamli H, Li L, Gobe GC. Limitations to the therapeutic potential of tyrosine kinase inhibitors and alternative therapies for kidney Cancer. Ochsner J. 2019;19(2):138\u201351. https:\/\/doi.org\/10.31486\/toj.18.0015.","journal-title":"Ochsner J"},{"key":"101_CR37","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1159\/000439008","volume":"55","author":"S Sarwar","year":"2016","unstructured":"Sarwar S, Bakbak B, Sadiq MA, Sepah YJ, Shah SM, Ibrahim M, et al. Fusion proteins: Aflibercept (VEGF trap-eye). Dev Ophthalmol. 2016;55:282\u201394. https:\/\/doi.org\/10.1159\/000439008.","journal-title":"Dev Ophthalmol"},{"issue":"5","key":"101_CR38","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","volume":"30","author":"HY Small","year":"2014","unstructured":"Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol. 2014;30(5):534\u201343. https:\/\/doi.org\/10.1016\/j.cjca.2014.02.011.","journal-title":"Can J Cardiol."},{"key":"101_CR39","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0","author":"Cancer Institute N","year":"2017","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 2017."},{"issue":"31","key":"101_CR40","doi-asserted-by":"publisher","first-page":"51492","DOI":"10.18632\/oncotarget.18190","volume":"8","author":"T Zhao","year":"2017","unstructured":"Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: a systematic review and comprehensive meta-analysis. Oncotarget. 2017;8(31):51492\u2013506. https:\/\/doi.org\/10.18632\/oncotarget.18190.","journal-title":"Oncotarget."},{"key":"101_CR41","first-page":"4751","volume":"9","author":"J Chen","year":"2015","unstructured":"Chen J, Lu Y, Zheng Y. Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials. Drug Des Devel Ther. 2015;9:4751\u201360.","journal-title":"Drug Des Devel Ther"},{"issue":"24","key":"101_CR42","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ETH Yeh","year":"2009","unstructured":"Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231\u201347. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.050.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"101_CR43","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1093\/cvr\/cvz022","volume":"115","author":"J Versmissen","year":"2019","unstructured":"Versmissen J, Mirabito Colafella KM, Koolen SLW, Danser AHJ. Vascular cardio-oncology: vascular endothelial growth factor inhibitors and hypertension. Cardiovasc Res. 2019;115(5):904\u201314. https:\/\/doi.org\/10.1093\/cvr\/cvz022.","journal-title":"Cardiovasc Res"},{"key":"101_CR44","first-page":"e1","volume":"71","author":"AK Pandey","year":"2018","unstructured":"Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, et al. Mechanisms of VEGF-Inhibitor Associated Hypertension and Vascular Disease. Hypertens Dallas Tex 1979. 2018;71:e1\u20138.","journal-title":"Hypertens Dallas Tex 1979"},{"key":"101_CR45","first-page":"159","volume":"25","author":"KN Syrigos","year":"2011","unstructured":"Syrigos KN, Karapanagiotou E, Boura P, Manegold C, Harrington K. Bevacizumab-induced hypertension: pathogenesis and management. BioDrugs Clin Immunother Biopharm Gene Ther. 2011;25:159\u201369.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"issue":"3","key":"101_CR46","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1345\/aph.1L426","volume":"43","author":"SM Gressett","year":"2009","unstructured":"Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother. 2009;43(3):490\u2013501. https:\/\/doi.org\/10.1345\/aph.1L426.","journal-title":"Ann Pharmacother"},{"key":"101_CR47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","volume":"182","author":"M Li","year":"2018","unstructured":"Li M, Kroetz DL. Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther. 2018;182:152\u201360. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.08.012.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"101_CR48","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.ygyno.2017.09.017","volume":"147","author":"MK Frey","year":"2017","unstructured":"Frey MK, Dao F, Olvera N, Konner JA, Dickler MN, Levine DA. Genetic predisposition to bevacizumab-induced hypertension. Gynecol Oncol. 2017;147(3):621\u20135. https:\/\/doi.org\/10.1016\/j.ygyno.2017.09.017.","journal-title":"Gynecol Oncol"},{"key":"101_CR49","doi-asserted-by":"crossref","unstructured":"McIntyre WF, Oqab Z, Hopman WM, Hammad N, Baranchuk A. Hypertension due to antiangiogenic cancer therapy with VEGF inhibitors: is autonomic nervous system toxicity another possible mechanism? Can J Cardiol. 2014;30(12):1733.","DOI":"10.1016\/j.cjca.2014.08.023"},{"key":"101_CR50","unstructured":"Anonymous. Avastin. Eur Med Agency. 2018; [cited 2020 Aug 8]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/avastin."},{"issue":"2","key":"101_CR51","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41416-019-0481-y","volume":"121","author":"C Plummer","year":"2019","unstructured":"Plummer C, Michael A, Shaikh G, Stewart M, Buckley L, Miles T, et al. Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK. Br J Cancer. 2019;121(2):109\u201316. https:\/\/doi.org\/10.1038\/s41416-019-0481-y.","journal-title":"Br J Cancer"},{"issue":"4","key":"101_CR52","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1093\/annonc\/mds593","volume":"24","author":"SR Shah","year":"2013","unstructured":"Shah SR, Gressett Ussery SM, Dowell JE, Marley E, Liticker J, Arriaga Y, et al. Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(4):960\u20135. https:\/\/doi.org\/10.1093\/annonc\/mds593.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"issue":"7","key":"101_CR53","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/j.cjca.2015.12.023","volume":"32","author":"AC Cameron","year":"2016","unstructured":"Cameron AC, Touyz RM, Lang NN. Vascular complications of Cancer chemotherapy. Can J Cardiol. 2016;32(7):852\u201362. https:\/\/doi.org\/10.1016\/j.cjca.2015.12.023.","journal-title":"Can J Cardiol"},{"issue":"1","key":"101_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","volume":"2","author":"RM Touyz","year":"2018","unstructured":"Touyz RM, Herrmann J. Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol. 2018;2(1):13. https:\/\/doi.org\/10.1038\/s41698-018-0056-z.","journal-title":"NPJ Precis Oncol"},{"issue":"5","key":"101_CR55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/CRD.0000000000000252","volume":"27","author":"JB Blanter","year":"2019","unstructured":"Blanter JB, Frishman WH. The preventive role of angiotensin converting enzyme inhibitors\/angiotensin-II receptor blockers and \u03b2-adrenergic blockers in Anthracycline- and Trastuzumab-induced Cardiotoxicity. Cardiol Rev. 2019;27(5):256\u20139. https:\/\/doi.org\/10.1097\/CRD.0000000000000252.","journal-title":"Cardiol Rev"},{"issue":"2","key":"101_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1291\/hypres.28.147","volume":"28","author":"S-I Miura","year":"2005","unstructured":"Miura S-I, Fujino M, Matsuo Y, Tanigawa H, Saku K. Nifedipine-induced vascular endothelial growth factor secretion from coronary smooth muscle cells promotes endothelial tube formation via the kinase insert domain-containing receptor\/fetal liver kinase-1\/NO pathway. Hypertens Res Off J Jpn Soc Hypertens. 2005;28(2):147\u201353. https:\/\/doi.org\/10.1291\/hypres.28.147.","journal-title":"Hypertens Res Off J Jpn Soc Hypertens"},{"issue":"5","key":"101_CR57","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/annonc\/mdn713","volume":"20","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol Off J Eur Soc Med Oncol. 2009;20(5):807\u201315. https:\/\/doi.org\/10.1093\/annonc\/mdn713.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"101_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/ajh\/hpt201","volume":"27","author":"P Kru\u017eliak","year":"2014","unstructured":"Kru\u017eliak P, Nov\u00e1k J, Nov\u00e1k M. Vascular endothelial growth factor inhibitor\u2013induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors. Am J Hypertens. 2014;27(1):3\u201313. https:\/\/doi.org\/10.1093\/ajh\/hpt201.","journal-title":"Am J Hypertens"},{"key":"101_CR59","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.gore.2016.06.002","volume":"17","author":"BR Corr","year":"2016","unstructured":"Corr BR, Breed C, Sheeder J, Weisdack S, Behbakht K. Bevacizumab induced hypertension in gynecologic cancer: does it resolve after completion of therapy? Gynecol Oncol Rep. 2016;17:65\u20138. https:\/\/doi.org\/10.1016\/j.gore.2016.06.002.","journal-title":"Gynecol Oncol Rep"},{"issue":"4","key":"101_CR60","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40261-014-0174-5","volume":"34","author":"W-X Qi","year":"2014","unstructured":"Qi W-X, Shen Z, Tang L-N, Yao Y. Risk of hypertension in cancer patients treated with aflibercept: a systematic review and meta-analysis. Clin Drug Investig. 2014;34(4):231\u201340. https:\/\/doi.org\/10.1007\/s40261-014-0174-5.","journal-title":"Clin Drug Investig"},{"issue":"5","key":"101_CR61","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(5):1367\u201373. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2328.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res."},{"key":"101_CR62","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","volume":"59","author":"P Valent","year":"2017","unstructured":"Valent P, Hadzijusufovic E, Hoermann G, F\u00fcreder W, Schernthaner G-H, Sperr WR, et al. Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML. Leuk Res. 2017;59:47\u201354. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.008.","journal-title":"Leuk Res"},{"issue":"3","key":"101_CR63","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/jch.12273","volume":"16","author":"Y Li","year":"2014","unstructured":"Li Y, Li S, Zhu Y, Liang X, Meng H, Chen J, et al. Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis. J Clin Hypertens Greenwich Conn. 2014;16(3):177\u201385. https:\/\/doi.org\/10.1111\/jch.12273.","journal-title":"J Clin Hypertens Greenwich Conn"},{"issue":"10032","key":"101_CR64","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","volume":"387","author":"NB Haas","year":"2016","unstructured":"Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Lond Engl. 2016;387(10032):2008\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(16)00559-6.","journal-title":"Lancet Lond Engl"},{"key":"101_CR65","first-page":"503","volume":"92","author":"K Eechoute","year":"2012","unstructured":"Eechoute K, van der Veldt AAM, Oosting S, MHW K, Wessels JAM, Gelderblom H, et al. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension. Clin Pharmacol Ther. 2012;92:503\u201310.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"101_CR66","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/1759-7714.12608","volume":"9","author":"Y Fu","year":"2018","unstructured":"Fu Y, Wei X, Lin L, Xu W, Liang J. Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors. Thorac Cancer. 2018;9(5):542\u20137. https:\/\/doi.org\/10.1111\/1759-7714.12608.","journal-title":"Thorac Cancer"},{"key":"101_CR67","doi-asserted-by":"publisher","unstructured":"B\u00e6k M\u00f8ller N, Budolfsen C, Grimm D, Kr\u00fcger M, Infanger M, Wehland M, et al. Drug-induced hypertension caused by multikinase inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in renal cell carcinoma treatment. Int J Mol Sci. 2019;20(19). https:\/\/doi.org\/10.3390\/ijms20194712.","DOI":"10.3390\/ijms20194712"},{"issue":"1","key":"101_CR68","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bju.12940","volume":"117","author":"J Rautiola","year":"2016","unstructured":"Rautiola J, Donskov F, Peltola K, Joensuu H, Bono P. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma. BJU Int. 2016;117(1):110\u20137. https:\/\/doi.org\/10.1111\/bju.12940.","journal-title":"BJU Int"},{"issue":"11","key":"101_CR69","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/bjc.2015.368","volume":"113","author":"F Donskov","year":"2015","unstructured":"Donskov F, Michaelson MD, Puzanov I, Davis MP, Bjarnason GA, Motzer RJ, et al. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. Br J Cancer. 2015;113(11):1571\u201380. https:\/\/doi.org\/10.1038\/bjc.2015.368.","journal-title":"Br J Cancer"},{"issue":"6","key":"101_CR70","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1093\/annonc\/mdv147","volume":"26","author":"H Izzedine","year":"2015","unstructured":"Izzedine H, Derosa L, Le Teuff G, Albiges L, Escudier B. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(6):1128\u201333. https:\/\/doi.org\/10.1093\/annonc\/mdv147.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol."},{"key":"101_CR71","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.redox.2015.09.007","volume":"6","author":"L Le\u00f3n-Mateos","year":"2015","unstructured":"Le\u00f3n-Mateos L, Mosquera J, Ant\u00f3n AL. Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. Redox Biol. 2015;6:421\u20135. https:\/\/doi.org\/10.1016\/j.redox.2015.09.007.","journal-title":"Redox Biol"},{"issue":"2 Suppl","key":"101_CR72","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.5489\/cuaj.67","volume":"1","author":"C Kollmannsberger","year":"2007","unstructured":"Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J. 2007;1(2 Suppl):S41\u201354. https:\/\/doi.org\/10.5489\/cuaj.67.","journal-title":"Can Urol Assoc J"},{"issue":"12","key":"101_CR73","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ejca.2014.05.013","volume":"50","author":"MS Ewer","year":"2014","unstructured":"Ewer MS, Suter TM, Lenihan DJ, Niculescu L, Breazna A, Demetri GD, et al. Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: a comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events. Eur J Cancer. 2014;50(12):2162\u201370. https:\/\/doi.org\/10.1016\/j.ejca.2014.05.013.","journal-title":"Eur J Cancer"},{"key":"101_CR74","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.seminoncol.2014.01.001","volume":"41","author":"MS Brose","year":"2014","unstructured":"Brose MS, Frenette CT, Keefe SM, Stein SM. Management of Sorafenib-Related Adverse Events: a Clinician\u2019s perspective. Semin Oncol. 2014;41:S1\u201316. https:\/\/doi.org\/10.1053\/j.seminoncol.2014.01.001.","journal-title":"Semin Oncol"},{"key":"101_CR75","first-page":"675","volume":"56","author":"HW Kappers Mari\u00ebtte","year":"2010","unstructured":"Kappers Mari\u00ebtte HW, van Esch Joep HM, Wim S, Stefan S, Jan DAH, van den Meiracker Anton H. Hypertension induced by the tyrosine kinase inhibitor Sunitinib is associated with increased circulating Endothelin-1 levels. Hypertension Am Heart Assoc. 2010;56:675\u201381.","journal-title":"Hypertension Am Heart Assoc"},{"issue":"12","key":"101_CR76","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16326","volume":"2","author":"LE Roeker","year":"2019","unstructured":"Roeker LE, Sarraf Yazdy M, Rhodes J, Goodfriend J, Narkhede M, Carver J, et al. Hypertension in patients treated with Ibrutinib for chronic lymphocytic leukemia. JAMA Netw Open. 2019;2(12):e1916326. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.16326.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"101_CR77","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/bjh.14708","volume":"178","author":"JP Laubach","year":"2017","unstructured":"Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, et al. A retrospective analysis of 3954 patients in phase 2\/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017;178(4):547\u201360. https:\/\/doi.org\/10.1111\/bjh.14708.","journal-title":"Br J Haematol"},{"issue":"10","key":"101_CR78","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng W-J, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327\u201337. https:\/\/doi.org\/10.1016\/S1470-2045(17)30578-8.","journal-title":"Lancet Oncol"},{"issue":"3","key":"101_CR79","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","volume":"17","author":"BB Hasinoff","year":"2017","unstructured":"Hasinoff BB, Patel D, Wu X. Molecular mechanisms of the Cardiotoxicity of the proteasomal-targeted drugs Bortezomib and Carfilzomib. Cardiovasc Toxicol. 2017;17(3):237\u201350. https:\/\/doi.org\/10.1007\/s12012-016-9378-7.","journal-title":"Cardiovasc Toxicol"},{"issue":"11","key":"101_CR80","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753\u201361. https:\/\/doi.org\/10.3324\/haematol.2013.089334.","journal-title":"Haematologica."},{"issue":"13","key":"101_CR81","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Berdeja JG, Niesvizky R, Lonial S, Laubach JP, Hamadani M, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 2014;15(13):1503\u201312. https:\/\/doi.org\/10.1016\/S1470-2045(14)71125-8.","journal-title":"Lancet Oncol."},{"issue":"17","key":"101_CR82","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral Ixazomib, Lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1516282.","journal-title":"N Engl J Med"},{"issue":"7","key":"101_CR83","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11912-020-00931-w","volume":"22","author":"P Wu","year":"2020","unstructured":"Wu P, Oren O, Gertz MA, Yang EH. Proteasome inhibitor-related Cardiotoxicity: mechanisms, diagnosis, and management. Curr Oncol Rep. 2020;22(7):66. https:\/\/doi.org\/10.1007\/s11912-020-00931-w.","journal-title":"Curr Oncol Rep"},{"issue":"5","key":"101_CR84","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ctrv.2011.09.002","volume":"38","author":"A Soultati","year":"2012","unstructured":"Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos M-A, et al. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38(5):473\u201383. https:\/\/doi.org\/10.1016\/j.ctrv.2011.09.002.","journal-title":"Cancer Treat Rev"},{"key":"101_CR85","first-page":"701","volume":"40","author":"J Nuver","year":"2004","unstructured":"Nuver J, Smit AJ, Sleijfer DT, van Gessel AI, van Roon AM, van der Meer J, et al. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer Oxf Engl 1990. 2004;40:701\u20136.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"key":"101_CR86","first-page":"18","volume":"24","author":"M Valentov\u00e1","year":"2011","unstructured":"Valentov\u00e1 M, Mladosievicov\u00e1 B. Coronary heart disease and hypertension as late effects of testicular cancer treatment--a minireview. Klin Onkol Cas Ceske Slov Onkol Spolecnosti. 2011;24:18\u201322.","journal-title":"Klin Onkol Cas Ceske Slov Onkol Spolecnosti"},{"issue":"3","key":"101_CR87","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2165\/00002018-199615030-00005","volume":"15","author":"G Navis","year":"1996","unstructured":"Navis G, Faber HJ, de Zeeuw D, de Jong PE. ACE inhibitors and the kidney. A risk-benefit assessment. Drug Saf. 1996;15(3):200\u201311. https:\/\/doi.org\/10.2165\/00002018-199615030-00005.","journal-title":"Drug Saf"},{"issue":"7","key":"101_CR88","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00467-011-1928-4","volume":"27","author":"JE Goodwin","year":"2012","unstructured":"Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. Pediatr Nephrol Berl Ger. 2012;27(7):1059\u201366. https:\/\/doi.org\/10.1007\/s00467-011-1928-4.","journal-title":"Pediatr Nephrol Berl Ger"},{"issue":"6","key":"101_CR89","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s11906-004-0046-0","volume":"6","author":"S Baid","year":"2004","unstructured":"Baid S, Nieman LK. Glucocorticoid excess and hypertension. Curr Hypertens Rep. 2004;6(6):493\u20139. https:\/\/doi.org\/10.1007\/s11906-004-0046-0.","journal-title":"Curr Hypertens Rep"},{"issue":"6","key":"101_CR90","first-page":"319","volume":"12","author":"S Arslansoyu Camlar","year":"2018","unstructured":"Arslansoyu Camlar S, Soylu A, Kavuk\u00e7u S. Cyclosporine in pediatric nephrology. Iran J Kidney Dis. 2018;12(6):319\u201330.","journal-title":"Iran J Kidney Dis"},{"key":"101_CR91","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1046\/j.1523-1755.62.s82.16.x","volume":"62","author":"JM Morales","year":"2002","unstructured":"Morales JM. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney Int Suppl. 2002;62:S81\u20137. https:\/\/doi.org\/10.1046\/j.1523-1755.62.s82.16.x.","journal-title":"Kidney Int Suppl"},{"issue":"7","key":"101_CR92","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1097\/00007890-199704150-00025","volume":"63","author":"M Bursztyn","year":"1997","unstructured":"Bursztyn M, Zelig O, Or R, Nagler A. Isradipine for the prevention of cyclosporine-induced hypertension in allogeneic bone marrow transplant recipients: a randomized, double-blind study. Transplantation. 1997;63(7):1034\u20136. https:\/\/doi.org\/10.1097\/00007890-199704150-00025.","journal-title":"Transplantation."},{"key":"101_CR93","first-page":"1915","volume":"2019","author":"Y-J Zhai","year":"1865","unstructured":"Zhai Y-J, Wu M-M, Linck VA, Zou L, Yue Q, Wei S-P, et al. Intracellular cholesterol stimulates ENaC by interacting with phosphatidylinositol-4,5-bisphosphate and mediates cyclosporine A-induced hypertension. Biochim Biophys Acta Mol basis Dis. 1865;2019:1915\u201324.","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"issue":"9","key":"101_CR94","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1097\/HJH.0b013e32833e0e74","volume":"28","author":"MP Schlaich","year":"2010","unstructured":"Schlaich MP, Grassi G. Sympathoexcitation in calcineurin inhibitor-induced hypertension: villain or innocent bystander? J Hypertens. 2010;28(9):1809\u201310. https:\/\/doi.org\/10.1097\/HJH.0b013e32833e0e74.","journal-title":"J Hypertens"},{"issue":"19","key":"101_CR95","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.2174\/0929867323666151221150052","volume":"23","author":"N Divac","year":"2016","unstructured":"Divac N, Naumovi\u0107 R, Stojanovi\u0107 R, Prostran M. The role of immunosuppressive medications in the pathogenesis of hypertension and efficacy and safety of antihypertensive agents in kidney transplant recipients. Curr Med Chem. 2016;23(19):1941\u201352. https:\/\/doi.org\/10.2174\/0929867323666151221150052.","journal-title":"Curr Med Chem"},{"key":"101_CR96","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.vph.2018.06.012","volume":"115","author":"K Marienhagen","year":"2019","unstructured":"Marienhagen K, Lehner F, Klempnauer J, Hecker H, Borlak J. Treatment of cyclosporine induced hypertension: results from a long-term observational study using different antihypertensive medications. Vasc Pharmacol. 2019;115:69\u201383. https:\/\/doi.org\/10.1016\/j.vph.2018.06.012.","journal-title":"Vasc Pharmacol"},{"key":"101_CR97","doi-asserted-by":"publisher","unstructured":"Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. Cochrane Database Syst Rev. 2006;(4):CD005161. https:\/\/doi.org\/10.1002\/14651858.CD005161.pub2.","DOI":"10.1002\/14651858.CD005161.pub2"},{"key":"101_CR98","first-page":"2147","volume":"18","author":"J Chanard","year":"2003","unstructured":"Chanard J, Toupance O, Lavaud S, Hurault de Ligny B, Bernaud C, Moulin B. Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2003;18:2147\u201353.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"101_CR99","first-page":"3","volume":"11","author":"G Vergoulas","year":"2007","unstructured":"Vergoulas G. Antihypertensive agents and renal transplantation. Hippokratia. 2007;11:3\u201312.","journal-title":"Hippokratia."},{"issue":"5","key":"101_CR100","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1681\/ASN.2015040466","volume":"27","author":"RA Lazelle","year":"2016","unstructured":"Lazelle RA, McCully BH, Terker AS, Himmerkus N, Blankenstein KI, Mutig K, et al. Renal deletion of 12 kDa FK506-binding protein attenuates Tacrolimus-induced hypertension. J Am Soc Nephrol JASN. 2016;27(5):1456\u201364. https:\/\/doi.org\/10.1681\/ASN.2015040466.","journal-title":"J Am Soc Nephrol JASN"},{"key":"101_CR101","doi-asserted-by":"publisher","unstructured":"Toral M, Romero M, Rodr\u00edguez-Nogales A, Jim\u00e9nez R, Robles-Vera I, Algieri F, Chueca-Porcuna N, S\u00e1nchez M, de la Visitaci\u00f3n N, Olivares M, Garc\u00eda F, P\u00e9rez-Vizca\u00edno F, G\u00e1lvez J, Duarte J. Lactobacillus fermentum Improves Tacrolimus-Induced Hypertension by Restoring Vascular Redox State and Improving eNOS Coupling. Mol Nutr Food Res. 2018:e1800033. https:\/\/doi.org\/10.1002\/mnfr.201800033.","DOI":"10.1002\/mnfr.201800033"},{"issue":"6","key":"101_CR102","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1016\/j.transproceed.2005.06.073","volume":"37","author":"TM Manzia","year":"2005","unstructured":"Manzia TM, De Liguori CN, Orlando G, Toti L, De Luca L, D\u2019Andria D, et al. Use of mycophenolate mofetil in liver transplantation: a literature review. Transplant Proc. 2005;37(6):2616\u20137. https:\/\/doi.org\/10.1016\/j.transproceed.2005.06.073.","journal-title":"Transplant Proc"},{"issue":"2","key":"101_CR103","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1159\/000315137","volume":"32","author":"CK Fujihara","year":"2010","unstructured":"Fujihara CK, Vieira JM, Sena CR, Ventura BH, Malheiros DM, Zatz R. Early brief treatment with losartan plus mycophenolate mofetil provides lasting renoprotection in a renal ablation model. Am J Nephrol. 2010;32(2):95\u2013102. https:\/\/doi.org\/10.1159\/000315137.","journal-title":"Am J Nephrol"},{"issue":"2","key":"101_CR104","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1177\/039156031007700201","volume":"77","author":"F Pinto","year":"2010","unstructured":"Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, et al. Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives. Urologia. 2010;77(2):71\u201383. https:\/\/doi.org\/10.1177\/039156031007700201.","journal-title":"Urologia."},{"issue":"1-2","key":"101_CR105","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jsbmb.2010.11.005","volume":"125","author":"TS Vasaitis","year":"2011","unstructured":"Vasaitis TS, Bruno RD, Njar VCO. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol. 2011;125(1-2):23\u201331. https:\/\/doi.org\/10.1016\/j.jsbmb.2010.11.005.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"101_CR106","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nrurol.2016.273","volume":"14","author":"A Veccia","year":"2017","unstructured":"Veccia A, Maines F, Kinspergher S, Galligioni E, Caffo O. Cardiovascular toxicities of systemic treatments of prostate cancer. Nat Rev Urol. 2017;14(4):230\u201343. https:\/\/doi.org\/10.1038\/nrurol.2016.273.","journal-title":"Nat Rev Urol"},{"key":"101_CR107","first-page":"1970","volume":"51","author":"R Iacovelli","year":"2015","unstructured":"Iacovelli R, Verri E, Cossu Rocca M, Aurilio G, Cullur\u00e0 D, De Cobelli O, et al. The incidence and relative risk of cardiovascular toxicity in patients treated with new hormonal agents for castration-resistant prostate cancer. Eur J Cancer Oxf Engl 1990. 2015;51:1970\u20137.","journal-title":"Eur J Cancer Oxf Engl 1990"},{"issue":"2","key":"101_CR108","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40264-018-0778-4","volume":"42","author":"G Curigliano","year":"2019","unstructured":"Curigliano G, Shah RR. Safety and tolerability of Phosphatidylinositol-3-kinase (PI3K) inhibitors in oncology. Drug Saf. 2019;42(2):247\u201362. https:\/\/doi.org\/10.1007\/s40264-018-0778-4.","journal-title":"Drug Saf"},{"key":"101_CR109","first-page":"821","volume":"31","author":"IB Greenwell","year":"2017","unstructured":"Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. Oncol Williston Park N. 2017;31:821\u20138.","journal-title":"Oncol Williston Park N"},{"issue":"9","key":"101_CR110","doi-asserted-by":"publisher","first-page":"14325","DOI":"10.18632\/oncotarget.9527","volume":"8","author":"M-D Canela","year":"2017","unstructured":"Canela M-D, Noppen S, Bueno O, Prota AE, Bargsten K, S\u00e1ez-Calvo G, et al. Antivascular and antitumor properties of the tubulin-binding chalcone TUB091. Oncotarget. 2017;8(9):14325\u201342. https:\/\/doi.org\/10.18632\/oncotarget.9527.","journal-title":"Oncotarget."},{"issue":"8","key":"101_CR111","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1158\/1078-0432.CCR-08-2710","volume":"15","author":"EL Schwartz","year":"2009","unstructured":"Schwartz EL. Antivascular actions of microtubule-binding drugs. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15(8):2594\u2013601. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-2710.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"24","key":"101_CR112","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542\u201350. https:\/\/doi.org\/10.1056\/NEJMoa061884.","journal-title":"N Engl J Med"},{"issue":"26","key":"101_CR113","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1056\/NEJMoa072113","volume":"357","author":"K Miller","year":"2007","unstructured":"Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666\u201376. https:\/\/doi.org\/10.1056\/NEJMoa072113.","journal-title":"N Engl J Med"},{"issue":"6","key":"101_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234541","volume":"15","author":"S Hoque","year":"2020","unstructured":"Hoque S, Chen BJ, Schoen MW, Carson KR, Keller J, Witherspoon BJ, et al. End of an era of administering erythropoiesis stimulating agents among veterans administration cancer patients with chemotherapy-induced anemia. PLoS One. 2020;15(6):e0234541. https:\/\/doi.org\/10.1371\/journal.pone.0234541.","journal-title":"PLoS One"},{"issue":"10","key":"101_CR115","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/ijc.32917","volume":"146","author":"MW Schoen","year":"2020","unstructured":"Schoen MW, Hoque S, Witherspoon BJ, Schooley B, Sartor O, Yang YT, et al. End of an era for erythropoiesis-stimulating agents in oncology. Int J Cancer. 2020;146(10):2829\u201335. https:\/\/doi.org\/10.1002\/ijc.32917.","journal-title":"Int J Cancer"},{"issue":"4","key":"101_CR116","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.clinthera.2014.02.007","volume":"36","author":"CA Forbes","year":"2014","unstructured":"Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, et al. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review. Clin Ther. 2014;36(4):594\u2013610. https:\/\/doi.org\/10.1016\/j.clinthera.2014.02.007.","journal-title":"Clin Ther"},{"issue":"5","key":"101_CR117","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0272-6386(99)70413-0","volume":"33","author":"ND Vaziri","year":"1999","unstructured":"Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis Off J Natl Kidney Found. 1999;33(5):821\u20138. https:\/\/doi.org\/10.1016\/S0272-6386(99)70413-0.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"issue":"8","key":"101_CR118","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, Bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1606038.","journal-title":"N Engl J Med"},{"issue":"5","key":"101_CR119","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1182\/blood.2019000722","volume":"134","author":"A Chari","year":"2019","unstructured":"Chari A, Martinez-Lopez J, Mateos M-V, Blad\u00e9 J, Benboubker L, Oriol A, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019;134(5):421\u201331. https:\/\/doi.org\/10.1182\/blood.2019000722.","journal-title":"Blood."},{"issue":"6","key":"101_CR120","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","volume":"178","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, et al. Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896\u2013905. https:\/\/doi.org\/10.1111\/bjh.14787.","journal-title":"Br J Haematol"},{"issue":"4","key":"101_CR121","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1046\/j.1365-2354.2003.00416.x","volume":"12","author":"LJM Costa","year":"2003","unstructured":"Costa LJM, Varella PCS, Del Giglio A. White coat effect in breast cancer patients undergoing chemotherapy. Eur J Cancer Care (Engl). 2003;12(4):372\u20133. https:\/\/doi.org\/10.1046\/j.1365-2354.2003.00416.x.","journal-title":"Eur J Cancer Care (Engl)"},{"key":"101_CR122","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ. Dennison Himmelfarb Cheryl, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines. Hypertension Am Heart Assoc. 2018;71:e13\u2013115.","journal-title":"Hypertension Am Heart Assoc"},{"issue":"5","key":"101_CR123","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s10552-017-0867-1","volume":"28","author":"AN Minlikeeva","year":"2017","unstructured":"Minlikeeva AN, Freudenheim JL, Cannioto RA, Szender JB, Eng KH, Modugno F, et al. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes Control CCC. 2017;28(5):469\u201386. https:\/\/doi.org\/10.1007\/s10552-017-0867-1.","journal-title":"Cancer Causes Control CCC"},{"issue":"10","key":"101_CR124","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. Authors\/Task Force Members: 2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens. 2018;36(10):1953\u20132041. https:\/\/doi.org\/10.1097\/HJH.0000000000001940.","journal-title":"J Hypertens"},{"issue":"2","key":"101_CR125","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s00408-014-9675-5","volume":"193","author":"M Iachina","year":"2015","unstructured":"Iachina M, Jakobsen E, M\u00f8ller H, L\u00fcchtenborg M, Mellemgaard A, Krasnik M, et al. The effect of different comorbidities on survival of non-small cells lung cancer patients. Lung. 2015;193(2):291\u20137. https:\/\/doi.org\/10.1007\/s00408-014-9675-5.","journal-title":"Lung."},{"issue":"20","key":"101_CR126","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1001\/jama.291.20.2441","volume":"291","author":"JF Piccirillo","year":"2004","unstructured":"Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441\u20137. https:\/\/doi.org\/10.1001\/jama.291.20.2441.","journal-title":"JAMA."},{"key":"101_CR127","first-page":"96","volume":"53","author":"D Goldstein","year":"2016","unstructured":"Goldstein D, Rosenberg JE, Figlin RA, Townsend RR, McCann L, Carpenter C, et al. Is change in blood pressure a biomarker of pazopanib and sunitinib efficacy in advanced\/metastatic renal cell carcinoma? Eur J Cancer Oxf Engl 1990. 2016;53:96\u2013104.","journal-title":"Eur J Cancer Oxf Engl 1990"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-021-00101-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40959-021-00101-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-021-00101-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T09:03:57Z","timestamp":1617699837000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-021-00101-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,6]]},"references-count":127,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["101"],"URL":"https:\/\/doi.org\/10.1186\/s40959-021-00101-2","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,6]]},"assertion":[{"value":"20 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}